These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 33805422)

  • 41. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.
    Bahramloo M; Shahabi SA; Kalarestaghi H; Rafat A; Mazloumi Z; Samimifar A; Asl KD
    Biomed Pharmacother; 2024 Aug; 177():117024. PubMed ID: 38941897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.
    Zha C; Song J; Wan M; Lin X; He X; Wu M; Huang R
    Ther Adv Hematol; 2024; 15():20406207241263489. PubMed ID: 39050113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
    Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
    Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. piggyBac system to co-express NKG2D CAR and IL-15 to augment the
    Du Z; Ng YY; Zha S; Wang S
    Mol Ther Methods Clin Dev; 2021 Dec; 23():582-596. PubMed ID: 34853803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
    Schorr C; Perna F
    Front Immunol; 2022; 13():1085978. PubMed ID: 36605213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers as targets for CAR-T/NK cell therapy in AML.
    Shao R; Li Z; Xin H; Jiang S; Zhu Y; Liu J; Huang R; Xu K; Shi X
    Biomark Res; 2023 Jun; 11(1):65. PubMed ID: 37330575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
    Kaito Y; Imai Y
    Int J Hematol; 2024 Jul; 120(1):34-43. PubMed ID: 38693419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
    Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
    MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
    Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular therapy for acute myeloid Leukemia - Current status and future prospects.
    Hansrivijit P; Gale RP; Barrett J; Ciurea SO
    Blood Rev; 2019 Sep; 37():100578. PubMed ID: 31109711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.